Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Radiofrequency ablation (RFA) of the renal sympathetic nerves is thought to decrease both the afferent sympathetic signals from the kidney to the brain and the efferent signals from the brain to the kidney. This procedure decreases sympathetic activation, decreases vasoconstriction, and decreases activation of the renin-angiotensin system. RFA of the renal sympathetic nerves has been proposed as a treatment option for patients with resistant hypertension.
The procedure is performed percutaneously with access at the femoral artery. A flexible catheter is threaded into the renal artery and controlled energy source, most commonly low-power RF energy, is delivered to the arterial walls where the renal sympathetic nerves are located. Once adequate RF energy has been delivered to ablate the sympathetic nerves, the catheter is removed.
Radiofrequency ablation of the renal sympathetic nerves as a treatment for resistant hypertension is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
There are currently no radiofrequency ablation (RFA) devices approved by the FDA for ablation of the renal sympathetic nerves as a treatment for hypertension. The strongest evidence comes from sham-controlled trials, the largest of which found no significant benefits with renal denervation. The evidence is insufficient to determine the effects of the technology on health outcomes.
American Heart Association, American College of Cardiology, & American Society of Hypertension. (2015). Treatment of hypertension in patients with coronary artery disease. Retrieved May 21, 2019 from https://www.acc.org/guidelines/guidelines.
BlueCross BlueShield Association. Evidence Positioning System. (9:2018). Radiofrequency ablation of the renal sympathetic nerves as a treatment for resistant hypertension (7.01.136). Retrieved May 21, 2019 from https://www.evidencepositioningsystem.com/. (48 articles and/or guidelines reviewed)
Bhatt, D., Kandzari, D., O’Neill, W., D’Agostino, R., Flack, J., Katzen, B., et al. (2014). A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine, 370, 1393-1401. (Level 1 evidence)
Elmula, F., Feng, Y., Jacobs, L., Larstorp, A., Kjeldsen, S., Persu, A., et al. (2017). Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure, 26 (4), 195-203. (Level 1 evidence)
Esler, M., Böhm, M., Sievert, H., Rump, C., Schmieder, R., Krum, H., et al. (2014). Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal, 35, 1752-1759. (Level 1 evidence)
Pappaccogli, M., Covella, M., Berra, E., Fulcheri, C., Di Monaco, S., Perlo, E., et al. (2018). Effectiveness of renal denervation in resistant hypertension: a meta-analysis of 11 controlled studies. High Blood Press Cardiovascular Prevention, doi: 10.1007/s40292-018-0260-5. [Epub ahead of print]
Pourmoghaddas, M., Khosravi, A., Akhbari, M., Akbari, M., Pourbehi, M., Ziaei, F., et al. (2016). One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension. ARYA Atherosclerosis, 12 (2), 109-113. Abstract retrieved August 4, 2016 from PubMed database.
Vogiatzakis, N., Tsioufis, C., Georgiopoulos, G., Thomopoulos, C., Dimitriadis, K., Kasiakogias, A., et al. (2017). Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. Journal of Hypertension, Doi: 10.1097/HJH.1391. Abstract retrieved June 1, 2017 from PubMed database.
Yao, Y., Zhang, D., Qian, J., Deng, S., Huang, Y., & Huang, J. (2016). The effect of renal denervation on resistant hypertension: meta-analysis of randomized controlled clinical trials. Clinical and Experimental Hypertension, 38 (3), 278-286. Abstract retrieved June 1, 2017 from PubMed database.
ORIGINAL EFFECTIVE DATE: 4/11/2013
MOST RECENT REVIEW DATE: 6/13/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.